Susquehanna International Group’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Susquehanna International Group’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-273,100	Closed	-$443K	–	14436
2021 Q4	$713K	Buy	273,100 +92,741	+51%	+$280K	﹤0.01%	8208
2021 Q3	$561K	Buy	180,359 +123,075	+215%	+$411K	﹤0.01%	9080
2021 Q2	$213K	Buy	57,284 +499	+0.9%	+$1.66K	﹤0.01%	11475
2021 Q1	$196K	Buy	56,785 +28,496	+101%	+$116K	﹤0.01%	11441
2020 Q4	$95K	Sell	28,289 -1,364	-5%	-$4.88K	﹤0.01%	10517
2020 Q3	$104K	Buy	29,653 +18,424	+164%	+$74.2K	﹤0.01%	9898
2020 Q2	$52K	Buy	+11,229	New	+$49.7K	﹤0.01%	9740
2019 Q2	–	Sell	-42,845	Closed	-$407K	–	11055
2019 Q1	$407K	Buy	+42,845	New	+$170K	﹤0.01%	6668

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Susquehanna International Group's PHAS Position: Q1 2022 in Review

Susquehanna International Group sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2022, closing a stake of 273,100 shares — an estimated $443K sold.

Susquehanna International Group first reported a position in PHAS in Q1 2019 and held it in 8 quarters. The position peaked at $713K in Q4 2021. 56 funds tracked by Wall St. Rank hold PHAS as of Q1 2022.

Susquehanna International Group reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Susquehanna International Group sold 273,100 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $443K.
Susquehanna International Group first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 8 quarters.
Susquehanna International Group's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $713K in Q4 2021.
56 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Susquehanna International Group's 13F filing for Q1 2022, filed 16 May 2022.